Geode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Geode Capital Management LLC bought a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 48,639 shares of the company’s stock, valued at approximately $1,239,000. Geode Capital Management LLC owned approximately 0.09% of Bicara Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in Bicara Therapeutics in the third quarter worth $177,169,000. FMR LLC bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $57,913,000. Braidwell LP bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $42,219,000. Janus Henderson Group PLC purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP bought a new position in Bicara Therapeutics during the 3rd quarter worth approximately $21,225,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target for the company. Finally, Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $43.00.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $15.25 on Friday. The company’s fifty day moving average price is $19.64. Bicara Therapeutics Inc. has a one year low of $15.15 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.